Investors in Ultragenyx Pharmaceutical Inc. May Join Class Action Lawsuit for Securities Fraud
Investors in Ultragenyx Pharmaceutical Inc. May Join Class Action Lawsuit for Securities Fraud
The Rosen Law Firm, a prominent advocate for investor rights, has issued a reminder for shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) about an important opportunity to demand justice. For those who purchased shares between August 3, 2023, and December 26, 2025, there is a pressing deadline to consider participating in a class action lawsuit aimed at addressing potential securities fraud. The deadline for serving as a lead plaintiff is April 6, 2026.
Why Consider Participation?
If you invested in Ultragenyx stock during the mentioned period and suffered losses exceeding $100,000, you may be eligible for compensation without any up-front costs, thanks to Rosen Law Firm’s contingency fee arrangement. This means that shareholders can seek legal redress on a no-win, no-fee basis.
To actively engage in this class action, interested individuals can fill out a form on their website here or contact attorney Phillip Kim, toll-free, at 866-767-3653 or via email at [email protected] for more information.
Understanding the Case
The core of the lawsuit revolves around allegations that Ultragenyx and certain defendants shared misleading information about the company’s expected outcomes from its pivotal Phase III studies involving setrusumab (UX 143), a treatment under investigation for Osteogenesis Imperfecta (OI). The lawsuit contends that investors were assured of favorable results concerning the drug's efficacy without being made aware of crucial negative aspects that could significantly skew these claims.
Key Allegations:
1. Misleading Statements: The lawsuit implies that leadership at Ultragenyx projected an overly optimistic trajectory for setrusumab based on its ability to reduce fracture rates in OI patients. However, contrary evidence suggested that while the drug could enhance bone density, there was insufficient correlation to decreased annual fracture rates, a fact allegedly concealed from investors.
2. Material Information Concealed: As outlined in the suit, while the company communicated a high level of confidence in its studies, they allegedly masked substantial risks associated with the research methods and data interpretations that could detrimentally impact results.
3. Inflated Security Prices: The issue central to the lawsuit is that the firm’s statements led to inflated stock prices, ultimately harming investors when the truth was uncovered, leading to significant financial damages.
The lawsuit posits that such disclosures and the subsequent plummeting of stock prices could have been mitigated through more transparent communications during the stock’s period of heightened market activity, aligning more closely with the realities of the clinical research data.
Join the Fight for Justice
The law firm encourages any investors who find themselves affected to consider their options carefully. The opportunity to serve as a lead plaintiff allows investors to be at the forefront of the class action, representing not only themselves but also their fellow shareholders.
Rosen Law Firm emphasizes the importance of selecting knowledgeable and experienced legal counsel for such delicate matters. Their proven record includes handling complex securities class actions, which assures prospective clients of their commitment and expertise in representing investor interests.
Conclusion
Investors in Ultragenyx Pharmaceutical Inc. who are interested in exploring their rights and potential recoveries should act quickly, especially given the impending deadline of April 6, 2026. Engaging with seasoned legal representatives may enhance the chances for recovery and help investors regain losses incurred during the tumultuous period of stock evaluation.
Follow Rosen Law Firm’s updates and reach out to their team for assistance in navigating this critical junction in pursuing your rights as an investor.
Contact: Laurence Rosen, Esq. and Phillip Kim, Esq.
Phone: 212-686-1060
Email: [email protected]
Visit Rosen Law Firm
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.